After finishing at $1.02 in the prior trading day, Amarin Corp ADR (NASDAQ: AMRN) closed at $0.96, down -6.18%. On the day, 1015206 shares were traded.
Ratios:
Our goal is to gain a better understanding of AMRN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.80 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On October 25, 2023, Jefferies Downgraded its rating to Hold which previously was Buy and also lowered its target price recommendation from $3 to $1.
Jefferies Upgraded its Hold to Buy on January 06, 2023, whereas the target price for the stock was revised from $1.30 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 22 ’24 when Holt Patrick bought 14,426 shares for $1.09 per share. The transaction valued at 15,724 led to the insider holds 314,426 shares of the business.
Ketchum Steven B sold 34,131 shares of AMRN for $26,963 on Dec 12 ’23. The Chief Scientific Officer now owns 566,100 shares after completing the transaction at $0.79 per share. On Aug 16 ’23, another insider, Holt Patrick, who serves as the President and CEO of the company, bought 300,000 shares for $1.04 each. As a result, the insider paid 312,315 and bolstered with 300,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.27 while its Price-to-Book (P/B) ratio in mrq is 0.71.
Stock Price History:
Over the past 52 weeks, AMRN has reached a high of $1.49, while it has fallen to a 52-week low of $0.65.
Shares Statistics:
A total of 408.82M shares are outstanding, with a floating share count of 407.25M. Insiders hold about 0.38% of the company’s shares, while institutions hold 23.55% stake in the company.
Earnings Estimates
Its stock is currently analyzed by Amazon.com, Inc. different market analysts. The consensus estimate for the next quarter is $267.28, with high estimates of $92.22 and low estimates of $0.96.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
